VANCOUVER, July 18, 2019 /PRNewswire-PRWeb/ -- Canadian entrepreneur Dr. Tyler Wish and National Access Cannabis Corp. ("NAC") (TSXV:META) today announced the official launch of NACBio ("NACBio" or the "Company"), a cannabis intelligence company that is committed to becoming the gold-standard for real world cannabis insights.

The Company's intelligence platform is utilizing modern data intelligence capabilities and information derived from large cohorts of cannabis users to provide cannabis product companies with data-driven insights for product development; and to offer cannabis retailers, medical providers, and consumers with evidence-based recommendations for selecting the best products.

Tyler Wish, CEO of NACBio commented, "One of the core challenges faced by both cannabis product companies and consumers today is a lack of precision and consistency in the product/customer experience. Variation in human biology, cannabis products, and consumer preferences can lead to a wide range of end-user experiences. We have assembled the NACBio intelligence platform to empower the next generation of cannabis innovation by enabling industry and consumers to gain a much deeper and data-driven understanding of the relationship between cannabis, human biology, and outcomes. In addition to our strategic relationship with NAC, we are in active discussions with other leading cannabis companies to form an industry intelligence consortium, to both contribute to, and benefit from NACBio's intelligence platform."

"Today we celebrate the public launch of NAC Bio Inc., a data intelligence company dedicated to supporting the commercialization of next-generation cannabis products to better meet the needs of patients and consumers," said Mark Goliger, CEO of NAC. "With 30 currently licensed locations in Alberta, Manitoba and Saskatchewan, NAC has successfully assisted tens of thousands of Canadians with secure, safe and responsible access to legal recreational cannabis in Canada."

"Under Dr. Tyler Wish's guidance, NACBio will utilize cutting-edge technologies and approaches from the domains of data-science, genomics and digital health to better understand how cannabis works and is used by patients and customers in the real world, leveraging NAC's robust and growing data set as well as information from several cannabis industry partners throughout the value chain. Over time, the NACBio intelligence platform, is expected to both enhance outcomes for patients and consumers while providing NAC and its partners with critical market insights that provide a competitive advantage, empower innovation, and drive future growth."

---- ENDS ----

For media inquiries, contact Sophie Kelk at Jive PR + Digital: sophie@jiveprdigital.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About NACBio

NACBio is a data intelligence firm focused on accelerating the digital research, innovation, and commercialization opportunities within the global cannabis industry. By connecting the dots between users, products, and outcomes at enormous breadth and scale, NACBio is enabling cannabis stakeholders to optimize outcomes by having a much deeper and data-driven understanding for how cannabis works in the real world. For more information, please visit nacbio.com.

About National Access Cannabis Corp.

NAC is Canada's largest recreational cannabis retailer by provincial store count. With a portfolio of 30 retail locations nationwide, NAC is the leader in secure, safe and responsible access to legal recreational cannabis in Canada. Through its Canada-wide network of Meta Cannabis Supply Co.™ and NewLeaf Cannabis™ recreational cannabis retail stores and NAC Medical's cannabis clinics and pharmacy partnerships, NAC enables the public and registered patients to gain knowledgeable access to Canada's network of authorized Licensed Producers of cannabis. NAC is listed on the TSX Venture Exchange under the symbol (TSXV:META).

About Tyler Wish

Tyler Wish is a Canadian biotechnology entrepreneur focused on data-driven medicine and computational drug discovery who received his PhD in medicine from Memorial University. He is the CEO of NACBio, a privately held cannabis intelligence firm that is engineering a deeper data-driven understanding of the relationship between cannabis and human biology.

Tyler previously co-founded Sequence Bio, a biotechnology company that is leading Newfoundland's 100,000-person genome sequencing initiative designed to advance big data drug discovery. Over the years, he and the company were profiled at numerous industry, investment and public-policy forums including BIO Investor Forum, The Precision Medicine World Conference, Canada 2020, and Bloomberg TV.

A key player in the broader Canadian innovation ecosystem, Tyler supported recent Canadian Federal Legislation (Genetic Non-Discrimination Act), was a member of BIOTECanada's Emerging Company CEO Advisory Committee and was appointed as one of ten Canadian Innovation Leaders by the Federal Minister of Innovation, Science and Economic Development. He is currently a board member for the Board of Actua, Canada's leading youth STEM education outreach organization.

SOURCE NACBio